疏血通联合依达拉奉治疗老年脑梗死患者的效果

Effects of Shuxuetong combined with Edaravone in treatment of elderly patients with cerebral infarction

目的:观察疏血通联合依达拉奉治疗老年脑梗死患者的效果。方法:选取2019年2月至2021年3月该院收治的102例老年脑梗死患者进行前瞻性研究,按照随机数字表法分为对照组和观察组各51例。对照组采用依达拉奉治疗,观察组在对照组的基础上联合疏血通治疗,比较两组治疗效果,治疗前后神经功能缺损程度[美国国立卫生研究院卒中量表(NIHSS)]评分、炎性因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平,以及不良反应发生率。结果:观察组治疗总有效率为96.08%,高于对照组的78.43%,差异有统计学意义(P<0.05);治疗后,两组NIHSS评分均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CRP、IL-6、TNF-α水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:疏血通联合依达拉奉治疗老年脑梗死患者可提高治疗总有效率,降低NIHSS评分和炎性因子水平,效果优于单纯依达拉奉治疗。

Objective:To observe effects of Shuxuetong combined with Edaravone in treatment of elderly patients with cerebral infarction.Methods:A prospective study was conducted on 102 elderly patients with cerebral infarction admitted to the hospital from February 2019 to March 2021.According to random number table method,they were divided into control group and observation group,51 cases in each group.The control group was treated with Edaravone,while the observation group was treated with Shuxuetong on the basis of that of the control group.The treatment effect,the degree of neurological deficit[national institutes of health stroke scale(NIHSS)]score,the inflammatory factor[C-reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)]levels,and the incidence of adverse reactions were compared between the two groups before and after the treatment,.Results:The total effective rate of treatment in the observation group was 96.08%,which was higher than 78.43%in the control group,and the difference was statistically significant(P<0.05).After the treatment,the NIHSS scores of the two groups were lower than those before the treatment,that of the observation group was lower than that of the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CRP,IL-6 and TNF-αin the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Shuxuetong combined with Edaravone in the treatment of the elderly patients with cerebral infarction can improve the total effective rate of treatment,reduce the NIHSS scores and the inflammatory factor levels.Moreover,it is superior to single Edaravone treatment.